期刊文献+

喜树碱类药物传递系统的研究进展 被引量:3

Advance of delivery systems for camptothecins
下载PDF
导出
摘要 目的对喜树碱类药物的一些特殊传递系统进行综述。方法通过文献检索,以脂质体、微球、聚合物载体等新型的传递系统为主,介绍近几年喜树碱类药物传递系统的研究进展。结果通过一些特殊的传递方法与策略,可以解决喜树碱类药物所存在的溶解度、稳定性、毒性和不良反应等问题。结论随着新的药物传递系统的不断成熟与发展,喜树碱类药物将是十分有潜力的一类抗肿瘤药物。 Objective To review some delivery systems for camptothecin and its analogs in recent years.Method Liposome,polymer carrier,microsphere and other delivery systems for camptothecin were reviewed in detail.Result The problems of camptothecin such as solubility,stability and side effects could be solved by special delivery methods and strategies.Conclusion As the development and maturation of some novel drug delivery system,camptothecin will be a kind of potential anticancer drugs.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2005年第4期315-320,共6页 Journal of Shenyang Pharmaceutical University
基金 国家新药研究基金项目(949720) 辽宁省教育厅重大项目计划(202043233)
关键词 喜树碱类药物 脂质体 微球 聚合物载体 camptothecin liposome microsphere polymer carrier
  • 相关文献

参考文献29

  • 1Wall ME, Wani MC, Cook CE. Plant antitumor agents: the isolation and structure of camptothecin, a novel alkaloid leukemia and tumor inhibitor from camptotheca acuminate [J]. J Am Chem Soc, 1966,88: 3888 - 3890.
  • 2Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues [J]. J Pharm Sci, 1992, 81: 676 - 684.
  • 3Burke TG. Liposomal stabilization of camptothecin' s lactone ring [J].J Am Chem Soc, 1990, 114:8318 -8319.
  • 4Burke TG, Mishra AK, Wani MC, et al. Lipid bilyer partitioning and stability of camptothecin drugs [J].Biochemistry, 1993, 32: 5352 - 5364.
  • 5Daoud SS, Fetouh MI, Giovaneua BC. Antitumor effect of liposome-incorporated camptothecin in human malignant xenografts[J]. Anti-cancer Drugs, 1995,6 (1):83 - 93.
  • 6Subramanian D, Muller MT. Liposomal encapsulation increases the activity of the topoisomerase Ⅰ inhibitor topotecan[J]. Oncol Res, 1995, 7(9): 461 - 469.
  • 7Liu J, Hong RL, Cheng WF, et al. Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation [J]. Anti-caner Drugs, 2002, 13:709 - 717.
  • 8Sadzuka Y, Hirotsu S, Hirota S. Effect of liposomalization on the antitumor activity; side effect and tissue distribution of CPT-11 [J]. Cancer Lett, 1998, 127:99 - 106.
  • 9Colbern GT, Dykes DJ, Engbers C, et al. Encapsulation of the topoisomerase Ⅰ inhibitor GL147211C in pegylated(STEALTH)liposome: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts [J].Clin Cancer Res, 1998, 4(12) :3077 - 3082.
  • 10Emerson DL, Bendele R, Brown E, et al. Antitumor efficacy pharmacokinetics, and biodistribution of NX211: a low clearance liposomal formulation of lurtotecan [J]. Clin Cancer Res, 2000, 6 (7): 2903 -2912.

同被引文献50

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部